Boston Scientific Bags nVision As M&A Roll Continues
Executive Summary
Boston Scientific has expanded its gynecology/urology portfolio with the acquisition of nVision Medical, the maker of the first US FDA-cleared device designed to collect cell samples from the fallopian tubes for early ovarian cancer diagnosis.
You may also be interested in...
Boston Scientific Sees Grim Q2 But Eyes Growth By Q4 Fueled By Product Launches
The big news at Boston Scientific's first-quarter earnings call was how badly the pandemic had impacted the second quarter so far, with sales down almost $500m in April. But the company said it already saw signs that procedure volumes were beginning to bounce back.
M&A Analysis – Deals March On In Big Month For Boston Scientific
Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.